Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal to Boost Heart Disease Portfolio

Novartis announced it will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at approximately $1.4 billion on a fully diluted basis. The Swiss pharmaceutical giant confirmed that both companies’ boards of directors have unanimously approved the transaction, which is expected to close in the fourth quarter of this year.

Tourmaline Bio specializes in developing innovative treatments for cardiovascular disease, with its lead candidate pacibekitug in focus. The therapy, which is Phase III-ready, targets systemic inflammation and shows potential as a treatment for atherosclerotic cardiovascular disease (ASCVD). According to Novartis, acquiring this asset strengthens and complements its existing cardiovascular portfolio, positioning the company to address one of the leading causes of death worldwide.

Under the agreement, Novartis will launch a tender offer to purchase all outstanding shares of Tourmaline common stock. Once completed, Tourmaline Bio will operate as an indirect, wholly owned subsidiary of Novartis. The acquisition not only provides Novartis with a late-stage pipeline drug but also demonstrates its strategy of investing in therapies with strong market potential in high-need therapeutic areas.

The deal underscores the growing importance of cardiovascular innovation, as major pharmaceutical players seek to expand treatment options for patients at risk of heart disease. By integrating Tourmaline’s pacibekitug into its portfolio, Novartis aims to accelerate clinical development and eventually bring a new targeted therapy to market.

With global demand for cardiovascular treatments continuing to rise, this acquisition highlights Novartis’ commitment to driving growth through strategic partnerships and advancing next-generation therapies for patients worldwide.